Table 3 Adverse effect of PSM-balancing high- and low-risk groups during induction chemotherapy.

From: Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma

Toxic Effect

Low-risk group

P valuec

High-risk group

P value

 

2 cycles (n = 247)

3 cycles (n = 247)

 

2 cycles (n = 213)

3 cycles (n = 213)

 
 

Grade 1-2a

Grade 3-4

Grade 1-2

Grade 3-4

 

Grade 1-2

Grade 3-4

Grade 1-2

Grade 3-4

 

Any Grade3-4d

/

61 (24.7)b

/

77 (31.2)

0.133

/

60 (28.2)

/

67 (31.5)

0.525

Haematologic

 Leukopenia

72 (29.1)

24 (9.7)

84 (34.0)

29 (11.7)

0.300

58 (27.2)

29 (13.6)

62 (29.1)

30 (14.1)

0.882

 Neutropenia

66 (26.7)

45 (18.2)

56 (22.7)

61 (24.7)

0.185

54 (25.4)

47 (22.1)

43 (20.2)

52 (24.4)

0.437

 Anaemia

149 (60.3)

2 (0.8)

164 (66.4)

3 (1.2)

0.305

146 (68.5)

2 (0.9)

158 (74.2)

4 (1.9)

0.243

 Thrombocytopenia

18 (7.3)

3 (1.2)

31 (12.6)

6 (2.4)

0.081

28 (13.1)

3 (1.4)

32 (15.0)

6 (2.8)

0.496

Non-Haematologic

 ALT increased

122 (49.4)

8 (3.2)

114 (46.2)

3 (1.2)

0.199

103 (48.4)

3 (1.4)

95 (44.6)

3 (1.4)

0.737

 AST increased

102 (41.3)

8 (3.2)

106 (42.9)

3 (1.2)

0.308

84 (39.4)

5 (2.3)

89 (41.8)

3 (1.4)

0.711

 Total bilirubin increased

48 (19.4)

4 (1.6)

49 (19.8)

5 (2.0)

0.936

37 (17.4)

2 (0.9)

40 (18.8)

3 (1.4)

0.834

 Creatinine increased

46 (18.6)

1 (0.4)

49 (19.8)

0 (0.0)

0.576

35 (16.4)

0 (0.0)

38 (17.8)

1 (0.5)

0.557

 Hypoalbuminemia

116 (47.0)

0 (0.0)

137 (55.5)

0 (0.0)

0.072

105 (49.3)

0 (0.0)

130 (61.0)

1 (0.5)

0.027

 Hypokalemia

59 (23.9)

1 (0.4)

63 (25.5)

1 (0.4)

0.916

52 (24.4)

0 (0.0)

53 (24.9)

2 (0.9)

0.361

 Hyponatremia

101 (40.9)

5 (2.0)

108 (43.7)

5 (2.0)

0.814

78 (36.6)

3 (1.4)

83 (39.0)

2 (0.9)

0.812

  1. PSM propensity score matching, ALT alanine aminotransferase, AST aspartate aminotransferase.
  2. aAll adverse effects were evaluated according to the CTCAE (Common Terminology Criteria for Adverse Events) Version 5.1, and graded as Grade 1–5. No Grade 5 appears during treatment.
  3. bCategorical variables (adverse effect grades) are presented as n (%), where n represents the number of patients with corresponding adverse effects, and (%) represents the proportion of patients in the respective group.
  4. cp value was calculated by chi-squared test, or Fisher’s exact test, as appropriate.
  5. dThe total number and proportion of patients who experienced any Grade 3–4 adverse effect during induction chemotherapy, regardless of the type of toxic effect.
Back to article page